Access to healthcare
Access to healthcare at AstraZeneca goes beyond our medicines. We provide healthcare solutions along a journey to improve health - from prevention and awareness, diagnosis, treatment, to post-treatment.
Health is key to a thriving society. Healthcare is our core business and at the heart of all we do. The mission of our company is to “push the boundaries of science to deliver life-changing medicines.” How do we do this?
- We help to ensure that our medicines get to people who need them by investing in health systems around the world.
- We are making changes to address affordability to help ensure our medicines are accessible
- We seek to expand disease prevention and treatment whenever possible, through screenings, awareness programmes and training healthcare professionals.
Our Access to healthcare approach supports the following Sustainable Development Goals (SDGs)
In Switzerland, we are active in the fields of data generation and disease prevention and education. Moreover we are supporting activities of local institutions and patient organizations within our therapeutic focus areas.
Support of data generation
AstraZeneca collaborates with partners and stakeholders to generate local evidence that will allow a better understanding of patient characteristics, treatment pathways and real-world outcomes across different diseases, with the ultimate goal to improve patient care and outcomes in Switzerland.
Swiss Asthma Registry
AstraZeneca was instrumental in driving the kick-off and support of the national registry for severe asthma, which will help to understand the burden of disease in Switzerland and inform future guidance to optimise patient management.
Alpine Tumor Immunology Registry (Alpine TIR)
AstraZeneca is running several real world-evidence initiatives in Switzerland for lung cancer and supports the Alpine Tumor Immunology Registry (Alpine TIR) of SAKK. Alpine TIR is a database that collects information from Swiss patients to analyse the use of these drugs in clinical practice in order to improve patient care and monitor health economic aspects.
Swiss Diabetes Registry
AstraZeneca has been supporting the SwissDiab study with the aim of establishing a Swiss Diabetes Registry. The SwissDiab Study collects data of all patients at the study centres, irrespective of type, duration of diabetes or treatment. This allows the evaluation of diabetes treatment strategies at these centres. Furthermore, risk indicators for micro- and macrovascular complications, mortality and costs and quality of life will be assessed.
AMIS Plus - Cardiovascular disease
AMIS Plus is a national registry which collects and analyses data on patients with acute myocardial infarction in the pre-admission, hospital and follow-up phases. Emphasis is placed on the evaluation of risk factors, diagnostics, urgent therapy strategies and treatment. AMIS Plus data are important for quality assurance, assessing guidelines, improving compliance with guidelines in clinical practice, verifying whether results of randomize clinical trials are translatable into everyday clinical practice, investigating patient groups not extensively studied in large randomized trials and improving therapeutic strategies. AstraZeneca supports AMIS Plus as a main sponsor.
Our commitment to disease prevention and education
In order to raise awareness on certain diseases and to better support patients and caregivers, we seek collaborative partnerships with patient organizations, medical associations and hospitals. Together we aim to develop programs that contribute to improving patients' health in Switzerland.
- "Lunge Zürich" and the University of Zurich in raising awareness on asthma. Together they launched the information campaign "Breathe more freely, live more freely: Earth Mission Asthma Control".
- the online platform www.asthma-info.ch which is part of this campaign. Here specialists and physicians explain to asthma patients and caregivers how to better control this chronic disease.
- the comic strip "Earth Mission Asthma Control", that was launched for this awareness campaign, and is also designed to help people better understand asthma.
- DIAfit - a structured program provided by diabetesschweiz to prevent or delay the onset of diabetes mellitus type 2 in patients with pathological glucose tolerance.
- Furthermore, AstraZeneca is a member of QualiCCare, an association committed to further improve patient care in Switzerland by implementing "best practices" in the care of chronic diseases, as well as SGED (Swiss Society for Endocrinology and Diabetology).
- the 2-year seminar "CAS Diagnostic Procedure for Cardiovascular and Renal Diseases" at the University of Zurich.
- the newly launched KARAMBA ambulatory cardiovascular rehabilitation at the Heart Centre of the University Hospital Basel.
This rehabilitation program includes an advanced exercise program as well as detailed information and patient education on cardiovascular health.
- the production of a brochure on ‘Knowledge - Understanding - Better Living’, including interactive patient education and an online platform with a focus on prevention provided by Swiss Heart Foundation.
- the evaluation of a national lung cancer screening program for the early diagnosis of lung cancer with the aim to improve prognosis and treatment outcomes for patients.
- the Swiss Academy of Multidisciplinary Oncology (SAMO), which is dedicated to promote continued education in multidisciplinary oncology and to provide an interaction platform for physicians from different specialties.
- the Alpine Tumor Immunology Register Registry (Alpine TIR) to analyse the use of immune-therapies in order to improve patient care and monitor health economic aspects in Switzerland.
Read more about access to healthcare at AstraZeneca in our Sustainability Report